What is US6596746B2 (and how does it relate to dasatinib)?
US6596746B2 is a U.S. patent titled around the “dasatinib” compound family. It is one of the earlier patent grants in the dasatinib portfolio and is commonly referenced in freedom-to-operate (FTO) and generic-entry analyses because it covers specific chemical aspects of dasatinib rather than later-use or formulation improvements.
Because your question names the patent number but not the claim you care about, the most practical way to interpret it is: US6596746B2 is part of the baseline intellectual property around dasatinib itself.
When would US6596746B2 expire?
For a U.S. patent, the typical expiry pattern is driven by filing/priority dates and any adjustments/extension. Without the document’s filing date details here, I cannot state an exact expiry date for US6596746B2. If you share the priority/filing date shown on the patent front page (or the patent’s “Filed” and “Priority” fields), I can compute the expected base term and explain how extensions might change it.
Can generics enter before this patent expires?
Usually not while a relevant claim is still in force, unless one of these applies:
- the generic product does not fall within the specific claim scope, or
- the patent is invalid or unenforceable, or
- the applicant wins an approval pathway that hinges on non-infringement/invalidity arguments for the listed patent(s).
In practice, generic companies often wait until the key “compound” patents (like ones in early portfolios) are no longer enforceable, or they litigate/design around depending on claim coverage.
What do people usually challenge in compound patents like this?
Challenges often focus on:
- whether the generic’s structure or substituted features actually practice the claimed embodiments,
- obviousness/non-obviousness of the claimed chemical matter at the relevant priority date,
- written description and enablement (whether the patent teaches what it claims),
- and inventorship/claim clarity issues.
If you tell me whether you want infringement scope or invalidity themes, I can focus the analysis.
Where do you see US6596746B2 in FTO or ANDA contexts?
When dasatinib generics are evaluated, the listing often includes both “compound” patents (covering the drug itself) and secondary patents (methods of treatment, formulations, salt forms, etc.). US6596746B2 is typically the kind of patent that impacts whether a product can lawfully be manufactured/sold in the U.S., depending on whether its claims map to the commercial product and whether it is still active.
To connect it to a specific commercial product (brand vs generic, and which strength), you’d need:
- the drug label/active ingredient form (free base vs salt),
- and which claims the FTO focuses on.
What I need from you to give a precise, actionable answer
If you want a precise result (expiry date, claim relevance, or whether it blocks generics), paste one of the following from the patent record:
- the patent’s priority date and filing date, or
- the “Claims” section you’re concerned about (even just claim 1), or
- the USPTO/Google Patents link for US6596746B2.
With that, I can tell you the expected term through calendar date and how that typically affects generic entry timing.
---
Sources
No sources were provided with your prompt, so I did not cite any documents. If you share a link (USPTO or Google Patents) for US6596746B2, I can cite the exact filing/priority/term data.